Traws Pharma, Inc. Accrued Liabilities, Current
Traws Pharma, Inc. (TRAW) had Accrued Liabilities, Current of $3.40 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $3.40M.
- 2026-03-31: Accrued Liabilities, Current $5.54M.
- 2025-12-31: Accrued Liabilities, Current $5.49M.
- 2025-09-30: Accrued Liabilities, Current $2.78M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $3.40M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $5.54M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $5.49M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $2.78M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.59M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.52M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $3.12M 10-K · filed 2026-04-15 |
| 2024-09-30 | $2.65M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.51M 10-Q · filed 2024-08-15 |
| 2024-03-31 | $2.63M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $3.38M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.30M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.37M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $4.10M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.96M 10-K · filed 2024-04-01 |
| 2022-09-30 | $3.35M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.23M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $2.60M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $3.13M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.75M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $2.98M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $3.11M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $4.96M 10-K · filed 2022-03-21 |
| 2020-09-30 | $3.34M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $3.38M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $2.50M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $3.79M 10-K · filed 2021-03-18 |
| 2019-09-30 | $3.45M 10-Q · filed 2019-11-12 |
| 2018-12-31 | $4.17M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |